Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

3D Ultrasound Uterine Characteristics of Women Undergoing IVF/ICSI Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02549235
Recruitment Status : Recruiting
First Posted : September 15, 2015
Last Update Posted : June 4, 2019
Sponsor:
Collaborator:
Imperial College Healthcare NHS Trust
Information provided by (Responsible Party):
Sotirios Saravelos, Imperial College Healthcare NHS Trust

Tracking Information
First Submitted Date September 11, 2015
First Posted Date September 15, 2015
Last Update Posted Date June 4, 2019
Actual Study Start Date May 1, 2019
Estimated Primary Completion Date March 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 29, 2019)
Clinical pregnancy [ Time Frame: 28 days from embryo transfer ]
Clinical pregnancy
Original Primary Outcome Measures
 (submitted: September 11, 2015)
  • Clinical pregnancy [ Time Frame: 28 days from embryo transfer ]
  • Clinical miscarriage [ Time Frame: until 12 weeks of pregnancy ]
Change History Complete list of historical versions of study NCT02549235 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: May 29, 2019)
  • Ectopic pregnancy [ Time Frame: 28 days from embryo transfer ]
    Ectopic pregnancy
  • Ongoing pregnancy [ Time Frame: 12 weeks from embryo transfer ]
    Ongoing pregnancy
  • Clinical miscarriage [ Time Frame: until 12 weeks of pregnancy ]
    Clinical miscarriage
Original Secondary Outcome Measures
 (submitted: September 11, 2015)
  • Ectopic pregnancy [ Time Frame: 28 days from embryo transfer ]
  • Ongoing pregnancy [ Time Frame: 12 weeks from embryo transfer ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title 3D Ultrasound Uterine Characteristics of Women Undergoing IVF/ICSI Treatment
Official Title 3D Ultrasound Uterine Characteristics of Women Undergoing IVF/ICSI Treatment
Brief Summary The purpose of this trial is to evaluate the morphological characteristics of the uterus with three-dimensional ultrasound (3DUS) at the time of IVF/ICSI treatment and correlate it to clinical outcomes. The uterus will be assessed in the 3D coronal plane and measurements will be performed to assess whether they correlate with clinical pregnancy rate, miscarriage rate and live birth rate.
Detailed Description

INTRODUCTION

There has been a lot of increased interest in the recent years in the prevalence and diagnosis of congenital uterine anomalies (Chan et al 2011; Saravelos et al 2008). This has been further intensified by the introduction of several new classifications for these malformations, including the most recent ESHRE-ESGE classification (Grimbizis et al, 2013).

Most of the clinical interest, and what affects daily clinical practice is the diagnosis and treatment of the septate uterus, which is the commonest anomaly amenable to treatment (Homer and Li, 2000). Since the new ESHRE-ESGE classification, which has introduced a new objective method for diagnosis of this anomaly, by measuring the percentage of fundal indentation and considering to be a septate uterus when it is >50%.

To our knowledge there have been no prospective studies as yet assessing women undergoing ART in order to demonstrate whether indeed the 3D US morphological characteristics (including the percentage of fundal indentation) are correlated to either clinical pregnancy or clinical miscarriage. Indeed, this is of upmost importance, as for example the decision to operate on a so-called septate uterus should be based on whether it has a true impact on clinical outcomes. This is all the more most topical in the present era of IVF/ICSI, and the new classifications for uterine anomalies, as certain authors have criticized the new ESHRE-ESGE classification as significantly over-diagnosing the septate uterus which risks causing unnecessary interventions (Ludwin et al, 2015). Meanwhile other 3D US morphological characteristics such as characterisation of the subendometrial layers/junctional zone and Cesarean scan niches my also prove to be correlated with clinical outcomes.

AIMS Aim: To determine whether and to what extent different 3D US morphological characteristics of the uterus impact the clinical outcomes of women undergoing IVF/ICSI.

PLAN OF INVESTIGATION Subject recruitment: Women with infertility will be recruited from the Assisted Reproductive Technology Unit of Hammersmith Hospital, London. It is often our routine clinical practice to offer 3D US to patients undergoing treatment and we are anticipating that over 90% of patients undergoing treatment will be willing to have this evaluation as part of their routine treatment.

Study design: Prospective cohort observational study.

Inclusion criteria: Described Elsewhere

Exclusion criteria: Described elswhere

Power calculation: To our knowledge no previous prospective study has been performed within a similar context, therefore a power calculation is not easily applicable. However, given that most recent similar retrospective study comparing arcuate versus normal uteri in women undergoing IVF/ICSI included 161 subjects, we will also aim to collect over 150 subjects.

Procedure: All ultrasound examinations will be performed using the GE Voluson series ultrasound machines, with a standard 3D transvaginal probe (model RIC5-9-D; 6.6 MHz central image frequency). The examination with 3DUS will be identical to the routine 2D examination including an acquisition of a 3D volume which takes a few seconds. The images will be shown instantly to the operator and can be stored digitally onto the hard disc attached to ultrasonography machine for subsequent analysis. For the purpose of homogeneity and to reduce operator bias, no more than three experienced operators will perform all 3DUS examinations.

Outcome measures: Described elsewhere

Data processing and analysis: The researchers will ensure the confidentiality of sensitive data by minimizing the number of personnel who handles subject data. The computer data will be encrypted as required to maximize security. Data processing for statistical analysis will be performed using the Statistical Packages of Social Sciences for Windows (SPSS, Inc). Data will be presented by percentage, mean and standard deviation, median and range where appropriate. Comparisons between groups will be carried out by Student T test for continuous variables, ANOVA for mean value comparisons, Chi-square/Fisher's exact test for categorical data. Stepwise logistic regression analysis may be performed as part of systematic analysis for primary outcomes. P-values of <0.05 will be considered significant.

Monitoring and interim analysis: As the study is perceived to be safe and poses no additional hazard, a Data Monitoring Committee and interim analysis is not considered necessary. There are no known adverse effects of routine ultrasound. No extra pain or discomfort is associated with the 3D US.

Consent: All subjects will be asked to consent for the performance of 2D/3D US which forms part of routine care in our unit.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Women with infertility undergoing IVF/ICSI at the Assisted Reproductive Technology Unit, Hammersmith Hospital, London.
Condition Infertility
Intervention Other: Ultrasound
Routine 2D/3D ultrasound assessment
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: May 29, 2019)
150
Original Estimated Enrollment
 (submitted: September 11, 2015)
530
Estimated Study Completion Date September 30, 2020
Estimated Primary Completion Date March 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Women undergoing IVF/ICSI in either fresh or frozen cycles.
  • Women whose endometrial cavity can be visualised adequately via US

Exclusion Criteria:

  • Women aged >42 years
  • Women whose endometrial cavity cannot be visualised adequately via US, such as large fibroids, adenomyosis, BMI>35, significant uterine retroflexion/retroversion
  • Previous uterine surgery (e.g. septum resection, adhesiolysis)
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years to 42 Years   (Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Sotirios H Saravelos, MRCOG +44 0203313 ext 3185 s.saravelos@imperial.ac.uk
Contact: Rehan Salim, MRCOG +44 0203313 ext 3185 rehan.salim@nhs.net
Listed Location Countries United Kingdom
Removed Location Countries Hong Kong
 
Administrative Information
NCT Number NCT02549235
Other Study ID Numbers CT-183/2015
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Sotirios Saravelos, Imperial College Healthcare NHS Trust
Study Sponsor Imperial College London
Collaborators Imperial College Healthcare NHS Trust
Investigators Not Provided
PRS Account Imperial College London
Verification Date June 2019